Roche Secures FDA Priority Review Of Enspryng In Thyroid Eye Disease; Decision Due October 2026

Genentech (Roche) said the FDA granted priority review for its supplemental BLA for Enspryng (satralizumab), a humanized monoclonal antibody. The FDA priority review designation is a positive regulatory catalyst that can shorten the review timeline and improve near-term prospects for label expansion. No financial impact was quantified in the announcement.

Analysis

Genentech (Roche) said the FDA granted priority review for its supplemental BLA for Enspryng (satralizumab), a humanized monoclonal antibody. The FDA priority review designation is a positive regulatory catalyst that can shorten the review timeline and improve near-term prospects for label expansion. No financial impact was quantified in the announcement.